Prior to joining Unigene, Martin worked for Affectis Pharmaceuticals, where he most recently served as the CEO of the company.

Palmer said that Alex brings tremendous expertise to Unigene, with over 20 years of experience in the life sciences, including a strong track record in business development at large and small companies.

“Unigene is now prepared to accelerate the implementation of our new strategy, which we believe will take us to the next growth platform, Martin said.

“This will be accomplished by maximising the assets in our drug delivery and manufacturing technology business unit, Unigene Biotechnologies, as well as managing and further progressing our advanced clinical-stage partnerships and active preclinical pipeline.”